Antibiotics in Chronic Respiratory Diseases

Antibiotics are commonly used in the management of respiratory disorders such as cystic fibrosis (CF), non-CF bronchiectasis, asthma and COPD. In those conditions long-term antibiotics can be delivered as nebulised aerosols or administered orally. In CF, nebulised colomycin or tobramycin improve lung function, reduce number of exacerbations and improve quality of life (QoL). Oral antibiotics, such as macrolides, have acquired wide use not only as anti-microbial agents but also due to their anti-inflammatory and pro-kinetic properties. In CF, macrolides such as azithromycin have been shown to improve the lung function and reduce frequency of infective exacerbations. Similarly macrolides have been shown to have some benefits in COPD including reduction in a number of exacerbations. In asthma, macrolides have been reported to improve some subjective parameters, bronchial hyperresponsiveness and airway inflammation; however have no benefits on lung function or overall asthma control. Macrolides have also been used with beneficial effects in less common disorders such as diffuse panbronchiolitis or post-transplant bronchiolitis obliterans syndrome.

 

    Related Conference of Antibiotics in Chronic Respiratory Diseases

    March 18-19, 2024

    53rd World Congress on Microbiology

    Zurich, Switzerland
    May 09-10, 2024

    16th International Virology Summit

    Barcelona, Spain
    June 10-11, 2024

    5th International Conference on Molecular Microbiology

    Barcelona, Spain

    Antibiotics in Chronic Respiratory Diseases Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in